Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Passage BIO, Inc.PASG · Entity 7829 | CFO | March 16, 2026 | March 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Passage BIO, Inc.
Report date March 16, 2026 · Filed March 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.64 · Expires 2035-03-16 | Direct | 15,610 |
Reported balance
After 2026-03-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-03-16 · Grant · Acquired 15,610 · Balance 15,610 F1: The stock option vests as to 1/48 of the total shares monthly beginning on April 16, 2026 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests as to 1/48 of the total shares monthly beginning on April 16, 2026 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 16, 2026 Filed Mar 18, 2026 20:07 UTC | Passage BIO, Inc. PASG · Entity 7829 | GrantEmployee Stock Option (right to buy) · Derivative | 15,610 | $0.00 Strike: $7.64 | $0.00 |
DisclosureSEC source: 0001987062-26-000002 · form4-03182026_080313.xml · derivative · entry 1 Borthwick Kathleen · CIK 0001987062 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,610 Underlying: Common Stock · 15,610 shares Expires 2035-03-16 F1 · derivative.exercise_date: The stock option vests as to 1/48 of the total shares monthly beginning on April 16, 2026 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| January 08, 2026 Filed Jan 12, 2026 21:03 UTC | Passage BIO, Inc. PASG · Entity 7829 | Exercise / conversionRestricted Stock Unit · Derivative | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001987062-26-000001 · form4-01122026_090110.xml · derivative · entry 3 Borthwick Kathleen · CIK 0001987062 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. F5 · derivative.exercise_date: 50% of the total RSUs will vest on January 8, 2026 and the remaining 50% of the RSUs will vest on January 8, 2027, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F5 · derivative.expiration_date: 50% of the total RSUs will vest on January 8, 2026 and the remaining 50% of the RSUs will vest on January 8, 2027, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| January 08, 2026 Filed Jan 12, 2026 21:03 UTC | Passage BIO, Inc. PASG · Entity 7829 | SaleCommon Stock | 2,062 | $18.44 | $38,022.04 |
DisclosureSEC source: 0001987062-26-000001 · form4-01122026_090110.xml · nonDerivative · entry 2 Borthwick Kathleen · CIK 0001987062 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,402 F3 · kind: The sale reported on this Form 4 represents an Issuer mandated sale by the Reporting Person to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs; it does not represent a discretionary trade by the Reporting Person. Pursuant to the Issuer's equity incentive plan, an award recipient's tax withholding obligations must be funded by a "sell to cover" transaction. F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold as part of a block trade for multiple security holders of the Issuer in multiple transactions at prices ranging from $18.13 to $19.3061 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 4 with regard to the block trade. Read SEC document |
| January 08, 2026 Filed Jan 12, 2026 21:03 UTC | Passage BIO, Inc. PASG · Entity 7829 | Exercise / conversionCommon Stock | 5,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001987062-26-000001 · form4-01122026_090110.xml · nonDerivative · entry 1 Borthwick Kathleen · CIK 0001987062 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,464 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. F2 · balance_after: Includes 200 shares acquired on May 15, 2025 and 200 shares acquired on November 15, 2025 under the 2020 Employee Stock Purchase Plan. Read SEC document |
| March 15, 2025 Filed Mar 18, 2025 21:12 UTC | Passage BIO, Inc. PASG · Entity 7829 | GrantEmployee Stock Option (right to buy) · Derivative | 278,386 | $0.00 Strike: $0.39 | $0.00 |
DisclosureSEC source: 0001415889-25-008443 · form4-03182025_090317.xml · derivative · entry 1 Borthwick Kathleen · CIK 0001987062 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 278,386 Underlying: Common Stock · 278,386 shares Expires 2035-03-15 F1 · derivative.exercise_date: The stock option vests as to 1/48 of the total shares monthly beginning on April 15, 2025 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| February 11, 2025 Filed Feb 12, 2025 21:21 UTC | Passage BIO, Inc. PASG · Entity 7829 | SaleCommon Stock | 3,183 | $0.53 | $1,685.72 |
DisclosureSEC source: 0001415889-25-003728 · form4-02122025_090233.xml · nonDerivative · entry 2 Borthwick Kathleen · CIK 0001987062 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,283 F3 · kind: The sale reported on this Form 4 represents an Issuer mandated sale by the Reporting Person to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs; it does not represent a discretionary trade by the Reporting Person. Pursuant to the Issuer's equity incentive plan, an award recipient's tax withholding obligations must be funded by a "sell to cover" transaction. F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold as part of a block trade for multiple security holders of the Issuer in multiple transactions at prices ranging from $0.51 to $0.58 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 4 with regard to the block trade. Read SEC document |
| February 10, 2025 Filed Feb 12, 2025 21:21 UTC | Passage BIO, Inc. PASG · Entity 7829 | Exercise / conversionRestricted Stock Unit · Derivative | 8,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-003728 · form4-02122025_090233.xml · derivative · entry 3 Borthwick Kathleen · CIK 0001987062 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. F5 · derivative.exercise_date: 1/3 of the RSUs vested on February 10, 2024 and 2/3 of the RSUs will vest on February 10, 2025, subject to the Reporting Person's continued service to the Issuer on each vesting date. F5 · derivative.expiration_date: 1/3 of the RSUs vested on February 10, 2024 and 2/3 of the RSUs will vest on February 10, 2025, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document |
| February 10, 2025 Filed Feb 12, 2025 21:21 UTC | Passage BIO, Inc. PASG · Entity 7829 | Exercise / conversionCommon Stock | 8,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-003728 · form4-02122025_090233.xml · nonDerivative · entry 1 Borthwick Kathleen · CIK 0001987062 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,466 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. F2 · balance_after: Includes 4,000 shares acquired on May 16, 2024 and 4,000 shares acquired on November 16, 2024 under the 2020 Employee Stock Purchase Plan. Read SEC document |
| January 15, 2025 Filed Dec 29, 2025 21:15 UTC | Passage BIO, Inc. PASG · Entity 7829 | GrantRestricted Stock Unit · Derivative | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001987062-25-000002 · form4-12292025_091215.xml · derivative · entry 1 Borthwick Kathleen · CIK 0001987062 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires not disclosed F1 · derivative.exercise_price: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: 50% of the total RSUs will vest on January 8, 2026 and the remaining 50% of the RSUs will vest on January 8, 2027, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F2 · derivative.expiration_date: 50% of the total RSUs will vest on January 8, 2026 and the remaining 50% of the RSUs will vest on January 8, 2027, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| March 15, 2024 Filed Mar 19, 2024 20:11 UTC | Passage BIO, Inc. PASG · Entity 7829 | GrantEmployee Stock Option (right to buy) · Derivative | 227,000 | $0.00 Strike: $1.50 | $0.00 |
DisclosureSEC source: 0001415889-24-008495 · form4-03192024_080352.xml · derivative · entry 1 Borthwick Kathleen · CIK 0001987062 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 227,000 Underlying: Common Stock · 227,000 shares Expires not disclosed F1 · derivative.exercise_date: The stock option vests as to 1/48 of the total shares monthly beginning on April 15, 2024 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F1 · derivative.expiration_date: The stock option vests as to 1/48 of the total shares monthly beginning on April 15, 2024 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| February 13, 2024 Filed Feb 14, 2024 00:36 UTC | Passage BIO, Inc. PASG · Entity 7829 | SaleCommon Stock | 1,470 | $0.97 | $1,425.90 |
DisclosureSEC source: 0001415889-24-003640 · form4-02142024_120246.xml · nonDerivative · entry 2 Borthwick Kathleen · CIK 0001987062 · SVP, INTERIM CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,466 F2 · kind: The sale reported on this Form 4 represents an Issuer mandated sale by the Reporting Person to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs; it does not represent a discretionary trade by the Reporting Person. Pursuant to the Issuer's equity incentive plan, an award recipient's tax withholding obligations must be funded by a "sell to cover" transaction. Read SEC document |
| February 10, 2024 Filed Feb 14, 2024 00:36 UTC | Passage BIO, Inc. PASG · Entity 7829 | Exercise / conversionRestricted Stock Unit · Derivative | 4,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-003640 · form4-02142024_120246.xml · derivative · entry 3 Borthwick Kathleen · CIK 0001987062 · SVP, INTERIM CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 4,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: 1/3 of the RSUs will vest on February 10, 2024 and 2/3 of the RSUs will vest on February 10, 2025, subject to the Reporting Person's continued service to the Issuer on each vesting date. F3 · derivative.expiration_date: 1/3 of the RSUs will vest on February 10, 2024 and 2/3 of the RSUs will vest on February 10, 2025, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document |
| February 10, 2024 Filed Feb 14, 2024 00:36 UTC | Passage BIO, Inc. PASG · Entity 7829 | Exercise / conversionCommon Stock | 4,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-003640 · form4-02142024_120246.xml · nonDerivative · entry 1 Borthwick Kathleen · CIK 0001987062 · SVP, INTERIM CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,936 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. Read SEC document |
| January 02, 2024 Filed Jan 3, 2024 21:20 UTC | Passage BIO, Inc. PASG · Entity 7829 | SaleCommon Stock | 10,672 | $0.91 | $9,711.52 |
DisclosureSEC source: 0001209191-24-000367 · doc4.xml · nonDerivative · entry 2 Borthwick Kathleen · CIK 0001987062 · SVP, Interim CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,936 F3 · kind: The sale reported on this Form 4 represents an Issuer mandated sale by the Reporting Person to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs; it does not represent a discretionary trade by the Reporting Person. Pursuant to the Issuer's equity incentive plan, an award recipient's tax withholding obligations must be funded by a "sell to cover" transaction. Read SEC document |
| December 31, 2023 Filed Jan 3, 2024 21:20 UTC | Passage BIO, Inc. PASG · Entity 7829 | Exercise / conversionRestricted Stock Unit · Derivative | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-24-000367 · doc4.xml · derivative · entry 3 Borthwick Kathleen · CIK 0001987062 · SVP, Interim CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer's common stock. F5 · derivative.exercise_date: 100% of the total restricted stock units vested on December 31, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F5 · derivative.expiration_date: 100% of the total restricted stock units vested on December 31, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| December 31, 2023 Filed Jan 3, 2024 21:20 UTC | Passage BIO, Inc. PASG · Entity 7829 | Exercise / conversionCommon Stock | 30,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-24-000367 · doc4.xml · nonDerivative · entry 1 Borthwick Kathleen · CIK 0001987062 · SVP, Interim CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,608 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. F2 · balance_after: Includes 3,082 shares acquired on May 13, 2022 and 3,526 shares acquired on November 15, 2023 under the 2020 Employee Stock Purchase Plan. Read SEC document |
| July 28, 2023 Filed Jul 28, 2023 22:34 UTC | Passage BIO, Inc. PASG · Entity 7829 | GrantEmployee Stock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $0.88 | $0.00 |
DisclosureSEC source: 0001209191-23-043725 · doc4.xml · derivative · entry 1 Borthwick Kathleen · CIK 0001987062 · SVP, Interim CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2033-07-27 F1 · derivative.exercise_date: The stock option vested as to 25% of the total shares on July 28, 2024, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.